Sleep

New data presented at SLEEP 2024 show sleep disorders including insomnia are only linked to worse quality of life when veterans do not also have PTSD.

A study presented at SLEEP 2024 found medicinal cannabis shows promise for improving sleep onset latency, quality, and duration in children with ASD.

New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.

A study presented at SLEEP 2024 found melatonin increased sleep latency and overall sleep quality and decreased awakenings.

A late-breaking abstract from SLEEP 2024 shows the effect of mandibular devices on respiratory effort, and its overall impact on OSA.

An alternative device to CPAP shows clinical benefit and long-term patient adherence in new SLEEP 2024 trial data.

A study presented at SLEEP 2024 found persistent or progressive insomnia symptoms are linked to a greater depression risk than subthreshold cases with gradual improvement.

Announced on May 29, 2024, data from the MDD3001 trial indicate use of seltorexant was associated with meaningful improvements in depressive symptoms and sleep disturbances.

New literature review data suggests doxazosin is related to less incident hypotension than prazosin, while providing clinical benefit, in PTSD patients with condition-related nightmares.

This sleep month in review features positive pipeline updates and treatments for improved sleep quality.

A new study found intensive topical therapy improves deep sleep and REM sleep for patients with psoriasis and atopic dermatitis after 2 weeks.

Topline data from the SURMOUNT-OSA studies provide insight into the effects of tirzepatide in OSA with obesity, with Lilly disclosing plans for a regulatory submission mid-year.

A new study explored increased health care utilization of children among several specific sleep disorders, race, and age.

A new study found patients with a BMI of 32 to 35 have lower odds of responding to the hypoglossal nerve stimulation for OSA compared to patients with a lower BMI.

This sleep month in review highlights the 6 top sleep pieces in March, from FDA news, topline data, and pieces exploring how daylight savings and long COVID impact sleep.

A phase 2 trial found KP1077 provides clinically meaningful benefits for idiopathic hypersomnia.

A new study found sleep and emotional well-being are impacted days before women get their period.

The SYMPHONY trial found reboxetine can significantly reduce cataplexy, excessive daytime sleepiness, cognitive impairment, depression, and anxiety for patients with narcolepsy.

With limited CBTi-trained psychologists, investigators assessed the effectiveness of a self-guided digital CBTi as another option, so people don’t have to turn to pills.

More than half of the participants were identified as insomnia sleepers and nappers, two suboptimal sleep patterns linked with an increased risk of a chronic condition.

After 5 years, laparoscopic Roux-en-Y gastric bypass cured OSA in 55.1% of patients, and only 20% of patients still had moderate or severe OSA.

Now, 4 years since the start of the pandemic, how has sleep been impacted? Sleep experts provide their perspective.

FDA issued a Complete Response Letter to Vanda Pharmaceuticals stating tasimelteon for treating insomnia cannot be approved in its current form due to identified deficiencies.